Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 4.2 0.00% 0.00
ACRX closed up 1.94 percent on Friday, June 15, 2018, on 1.58 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical ACRX trend table...

Date Alert Name Type % Chg
Jun 15 Upper Bollinger Band Walk Strength 0.00%
Jun 15 Wide Bands Range Expansion 0.00%
Jun 15 Above Upper BB Strength 0.00%
Jun 15 Overbought Stochastic Strength 0.00%
Jun 15 Up 3 Days in a Row Strength 0.00%
Jun 15 Up 4 Days in a Row Strength 0.00%
Jun 15 Upper Bollinger Band Touch Strength 0.00%
Jun 14 Expansion Breakout Bullish Swing Setup 1.94%
Jun 14 Wide Bands Range Expansion 1.94%
Jun 14 Above Upper BB Strength 1.94%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.75
52 Week Low 1.55
Average Volume 589,133
200-Day Moving Average 2.5092
50-Day Moving Average 2.8579
20-Day Moving Average 3.4785
10-Day Moving Average 3.752
Average True Range 0.1926
ADX 53.48
+DI 40.96
-DI 7.75
Chandelier Exit (Long, 3 ATRs ) 3.7222
Chandelier Exit (Short, 3 ATRs ) 3.4278
Upper Bollinger Band 4.1923
Lower Bollinger Band 2.7647
Percent B (%b) 1.01
BandWidth 41.040678
MACD Line 0.3471
MACD Signal Line 0.3006
MACD Histogram 0.0465
Fundamentals Value
Market Cap 190.59 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -3.82
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.43
Resistance 3 (R3) 4.43 4.37 4.39
Resistance 2 (R2) 4.37 4.31 4.36 4.37
Resistance 1 (R1) 4.28 4.27 4.33 4.28 4.36
Pivot Point 4.22 4.22 4.24 4.21 4.22
Support 1 (S1) 4.13 4.16 4.18 4.13 4.04
Support 2 (S2) 4.07 4.12 4.06 4.03
Support 3 (S3) 3.98 4.07 4.01
Support 4 (S4) 3.98